Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

Robert Haddad; A. Dimitrios Colevas; Jeffrey F. Krane; Dennis Cooper; Bonnie Glisson; Philip C. Amrein; Linda Weeks; Rosemary Costello; Marshall Posner

doi:10.1016/S1368-8375(03)00097-6

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

Robert Haddad, A. Dimitrios Colevas, Jeffrey F. Krane, Dennis Cooper, Bonnie Glisson, Philip C. Amrein, Linda Weeks, Rosemary Costello, Marshall Posner

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

220 Scopus citations

Abstract

Phase II study of Herceptin® (Trastuzumab) in patients with advanced salivary gland tumors overexpressing Her2/neu. Patients with advanced, incurable salivary gland tumors and 2+ or 3+ Her2/neu expression in their tumors were enrolled in the study. After an initial dose of 4 mg/kg, patients received 2 mg/kg weekly. Patients were treated until they experienced progression of disease or unacceptable toxicity. The study was closed early when it has become clear that the majority of tumors screened did not overexpress Her2/neu. Fourteen patients were enrolled in the study. A total of 86 cycles of Herceptin were delivered with a median of three cycles per patient (range 1-40). Median time to progression was 4.2 months. One patient with metastatic mucoepidermoid carcinoma has received 40 cycles of Herceptin to date with a documented partial response. Herceptin given as a single agent has a low activity in salivary gland tumors overexpressing Her2/neu. New agents are still needed.

Original language	English (US)
Pages (from-to)	724-727
Number of pages	4
Journal	Oral Oncology
Volume	39
Issue number	7
DOIs	https://doi.org/10.1016/S1368-8375(03)00097-6
State	Published - Oct 2003

Keywords

Her2/Neu
Herceptin
Salivary gland tumors

ASJC Scopus subject areas

Oral Surgery
Oncology
Cancer Research

Access to Document

10.1016/S1368-8375(03)00097-6

Cite this

@article{4b89713279f0439a8b993aab18db8d0a,

title = "Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study",

abstract = "Phase II study of Herceptin{\textregistered} (Trastuzumab) in patients with advanced salivary gland tumors overexpressing Her2/neu. Patients with advanced, incurable salivary gland tumors and 2+ or 3+ Her2/neu expression in their tumors were enrolled in the study. After an initial dose of 4 mg/kg, patients received 2 mg/kg weekly. Patients were treated until they experienced progression of disease or unacceptable toxicity. The study was closed early when it has become clear that the majority of tumors screened did not overexpress Her2/neu. Fourteen patients were enrolled in the study. A total of 86 cycles of Herceptin were delivered with a median of three cycles per patient (range 1-40). Median time to progression was 4.2 months. One patient with metastatic mucoepidermoid carcinoma has received 40 cycles of Herceptin to date with a documented partial response. Herceptin given as a single agent has a low activity in salivary gland tumors overexpressing Her2/neu. New agents are still needed.",

keywords = "Her2/Neu, Herceptin, Salivary gland tumors",

author = "Robert Haddad and Colevas, {A. Dimitrios} and Krane, {Jeffrey F.} and Dennis Cooper and Bonnie Glisson and Amrein, {Philip C.} and Linda Weeks and Rosemary Costello and Marshall Posner",

note = "Funding Information: Supported in part by a grant from Genentech and support from the generosity of our patients and their families. ",

year = "2003",

month = oct,

doi = "10.1016/S1368-8375(03)00097-6",

language = "English (US)",

volume = "39",

pages = "724--727",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier Limited",

number = "7",

}

TY - JOUR

T1 - Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

AU - Haddad, Robert

AU - Colevas, A. Dimitrios

AU - Krane, Jeffrey F.

AU - Cooper, Dennis

AU - Glisson, Bonnie

AU - Amrein, Philip C.

AU - Weeks, Linda

AU - Costello, Rosemary

AU - Posner, Marshall

N1 - Funding Information: Supported in part by a grant from Genentech and support from the generosity of our patients and their families.

PY - 2003/10

Y1 - 2003/10

N2 - Phase II study of Herceptin® (Trastuzumab) in patients with advanced salivary gland tumors overexpressing Her2/neu. Patients with advanced, incurable salivary gland tumors and 2+ or 3+ Her2/neu expression in their tumors were enrolled in the study. After an initial dose of 4 mg/kg, patients received 2 mg/kg weekly. Patients were treated until they experienced progression of disease or unacceptable toxicity. The study was closed early when it has become clear that the majority of tumors screened did not overexpress Her2/neu. Fourteen patients were enrolled in the study. A total of 86 cycles of Herceptin were delivered with a median of three cycles per patient (range 1-40). Median time to progression was 4.2 months. One patient with metastatic mucoepidermoid carcinoma has received 40 cycles of Herceptin to date with a documented partial response. Herceptin given as a single agent has a low activity in salivary gland tumors overexpressing Her2/neu. New agents are still needed.

AB - Phase II study of Herceptin® (Trastuzumab) in patients with advanced salivary gland tumors overexpressing Her2/neu. Patients with advanced, incurable salivary gland tumors and 2+ or 3+ Her2/neu expression in their tumors were enrolled in the study. After an initial dose of 4 mg/kg, patients received 2 mg/kg weekly. Patients were treated until they experienced progression of disease or unacceptable toxicity. The study was closed early when it has become clear that the majority of tumors screened did not overexpress Her2/neu. Fourteen patients were enrolled in the study. A total of 86 cycles of Herceptin were delivered with a median of three cycles per patient (range 1-40). Median time to progression was 4.2 months. One patient with metastatic mucoepidermoid carcinoma has received 40 cycles of Herceptin to date with a documented partial response. Herceptin given as a single agent has a low activity in salivary gland tumors overexpressing Her2/neu. New agents are still needed.

KW - Her2/Neu

KW - Herceptin

KW - Salivary gland tumors

UR - http://www.scopus.com/inward/record.url?scp=0042703590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042703590&partnerID=8YFLogxK

U2 - 10.1016/S1368-8375(03)00097-6

DO - 10.1016/S1368-8375(03)00097-6

M3 - Article

C2 - 12907212

AN - SCOPUS:0042703590

SN - 1368-8375

VL - 39

SP - 724

EP - 727

JO - Oral Oncology

JF - Oral Oncology

IS - 7

ER -

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this